

PORTEC-4a: Randomised trial of standard or molecular profile-based recommendation for radiotherapy after surgery for women with early stage endometrial cancer

Submission date 03/06/2016	Recruitment status No longer recruiting	☐ Prospectively registered ☒ Protocol
Registration date 24/06/2016	Overall study status Ongoing	☐ Statistical analysis plan ☒ Results
Last Edited 06/01/2026	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

Background and study aims

For women with early stage endometrial (womb) cancer, current standard treatment is surgery (removal of the uterus and ovaries) followed by vaginal brachytherapy. Vaginal brachytherapy is a type of radiotherapy where a special applicator is placed in the vagina in which a small pellet of radioactive material is placed to give radiation treatment to the inner part of the vagina. With brachytherapy, the risk of local recurrence (that is, the tumour coming back) is very low and there are very few side effects. However, many women are treated with vaginal brachytherapy, while only few really need this. About 10 women have to be treated to prevent 1 vaginal recurrence. If local recurrence is found, this can be effectively treated at that time. Therefore, treating all women considered to be at risk seems unnecessary. If a better way of predicting which women are likely to suffer a relapse (vaginal recurrence) can be developed then not so many women have to undergo vaginal brachytherapy. This, in turn, will reduce health care costs. In recent years, scientific studies have shown that there are specific alterations in the genes of tumor cells which enable recurrence and the spread of cancer. For endometrial cancer, a better individual risk prediction has been obtained by combining known risk factors with individual alterations in the genes of their tumor. By determining this risk profile on the tumor tissue which has been removed at surgery, a better recommendation can be obtained as to what treatment should be performed, including whether or not vaginal brachytherapy is required

Objectives and design:

In the PORTEC-4a trial, the standard vaginal brachytherapy (standard treatment) will be compared to the use of the individual risk profile to determine adjuvant treatment (favorable: observation; intermediate: vaginal brachytherapy; unfavorable: external beam radiotherapy). The aim is to evaluate if the use of the individual risk profile saves many women unnecessary vaginal brachytherapy with similarly high recurrence-free survival and local control, and reduced health costs.

This is a randomised trial, and eligible and consenting women will be randomly assigned (1:2) to vaginal brachytherapy (standard arm) or molecular profile-based recommendations for either observation, vaginal brachytherapy or external beam radiotherapy (investigational arm).

Who can participate?

Women of any age (above 18) who have had surgery (removal of uterus and ovaries) for early stage endometrial cancer.

What does the study involve?

Participants are randomly allocated to one of two groups. Those in group 1 (control group) have vaginal brachytherapy as usual. Those in group 2 (intervention group) either have no further treatment after surgery, vaginal brachytherapy or external beam radiation therapy, depending upon their molecular profile (that is, the type of alterations in the genes of the tumor cells). All participants are then followed up for at least 5 years to check for recurrence of the tumor, quality of life and any side effects.

What are the possible benefits and risks of participating?

Possible benefits include being spared from further treatment after surgery and have a better understanding what the individual risk of recurrence is.

Where is the study run from?

Lead center is Leiden University Medical Center in the Netherlands. Participating centres are found in all regions of the Netherlands.

When is study starting and how long is it expected to run for?

June 2016 to December 2028

Who is funding the study?

Dutch Cancer Society.

Who is the main contact?

Professor Carien Creutzberg

Contact information

Type(s)

Scientific

Contact name

Prof Carien Creutzberg

ORCID ID

<https://orcid.org/0000-0002-7008-4321>

Contact details

Leiden University Medical Centre,
Dept of Radiation Oncology, K1-P,
Albinusdreef 2,
Leiden
Netherlands
2333 ZA

+31.71.526.5120
c.l.creutzberg@lumc.nl

Type(s)
Scientific

Contact name
Dr Anne-Sophie V.M. van den Heerik

ORCID ID
<https://orcid.org/0000-0001-6403-0143>

Contact details
Leiden University Medical Center, Dept of Radiation Oncology
Albinusdreef 2
Leiden
Netherlands
2333 ZA
+31 (0)71 526 5539
a.v.m.van_den_heerik@lumc.nl

Additional identifiers

ClinicalTrials.gov (NCT)
NCT03469674

Protocol serial number
UL2011-5336; P16.054; NL56828.058.16

Study information

Scientific Title
PORTEC-4a: Randomised Phase III Trial of molecular profile-based versus standard recommendations for adjuvant radiotherapy for women with early stage endometrial cancer

Acronym
PORTEC-4a

Study objectives
Molecular risk profile-based recommendations for no additional treatment (55%), vaginal brachytherapy (40%) or external beam radiotherapy (5%) will lead to similar vaginal control for women with early stage endometrial cancer with high-intermediate risk features, while sparing about 50% of these women vaginal brachytherapy and reducing health care usage.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Committee for Medical Ethics, Leiden University Medical Center, Leiden, The Netherlands, 10/05/2016, ref: P16.054

Primary study design

Interventional

Study design

Randomised multicenter phase III trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Endometrial cancer

Interventions

Participants are randomly allocated to one of two arms:

1. Standard arm:

Vaginal brachytherapy (3 short outpatient internal radiation treatments over 2 weeks to the vaginal cuff), based on PORTEC-2 trial.

2. Investigational arm:

Based on the molecular profile, either no further treatment after surgery (for favourable profile), or vaginal brachytherapy (as above, for intermediate profile) or external beam radiation therapy (5 weeks of daily out-patient external radiation treatments to the pelvic area, for unfavourable profile).

After completion of patient recruitment, follow-up will continue until the time of final analysis is reached and until at least 5 years after inclusion of each patient.

Intervention Type

Other

Primary outcome(s)

Vaginal recurrence, measured during each follow-up visit by vaginal inspection and pelvic examinations (3 monthly first 2 years, 6 monthly until 5th year) and confirmation by histology in case of suspected recurrence

Key secondary outcome(s)

1. Recurrence-free survival - regular follow-up visits (3 monthly first 2 years, 6 monthly until 5th year) with history focused on symptoms and side effects and pelvic examination; further evaluation in case of suspected recurrence locally or at distant sites by (PET)-CT and/or MRI scanning and histological confirmation. In case of death, information on date and cause of death are recorded
2. 5-year vaginal control - local recurrence free at 5 years either without any evidence of recurrence or after treatment for vaginal recurrence
3. Quality of life- Patients receive a QoL questionnaire consisting of EORTC QLQ-C30 and EN24 at baseline (after surgery, before study treatment or observation), at 6 weeks after randomisation, and at 6, 12, 18, 24, 36 and 60 months after randomisation
4. Side effects- Regular follow-up visits (3 monthly first 2 years, 6 monthly until 5th year) with history focused on symptoms and side effects – recording of adverse events according to CTCAEv 4.0

5. Health care costs - EC-related healthcare costs will include the costs of the randomised care and care associated with (serious) adverse events. Healthcare use over the follow-up period will be converted to costs using standard prices, discounted over time. Costs will be evaluated at each follow-up and at recurrence by recording hospital admissions, surgeries, etc over the past follow-up period

Completion date

31/12/2028

Eligibility

Key inclusion criteria

Histologically confirmed endometrioid type endometrial carcinoma, FIGO 2009 stage I, with one of the following combinations of stage, grade, age, and LVSI:

1. Stage IA, grade 3 (any age, with or without LVSI)
2. Stage IB, grade 1 or 2 and age >60 years
3. Stage IB, grade 1-2 with documented LVSI
4. Stage IB, grade 3 without LVSI
5. Stage II (microscopic), grade 1

WHO-performance status 0-2

Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Total final enrolment

569

Key exclusion criteria

1. Any other stage and type of endometrial carcinoma
2. Histological types papillary serous carcinoma or clear cell carcinoma (at least 10% if mixed type)
3. Undifferentiated or neuroendocrine carcinoma
4. Uterine sarcoma (including carcinosarcoma)
5. Previous malignancy (except for non-melanomatous skin cancer) < 5 yrs
6. Previous pelvic radiotherapy
7. Interval between the operation and start of radiotherapy exceeding 8 weeks

Updated 17/08/2021:

7. Expected interval between the operation and start of radiotherapy exceeding 8 weeks

Date of first enrolment

01/06/2016

Date of final enrolment

24/12/2021

Locations

Countries of recruitment

Austria

Belgium

Czech Republic

France

Germany

Ireland

Netherlands

Switzerland

Study participating centre

Leiden University Medical Center (lead center)

Netherlands

2333 ZA Leiden

Study participating centre

Academic Medical Center

Amsterdam

Netherlands

-

Study participating centre

Catharina Hospital

Eindhoven

Netherlands

-

Study participating centre

Erasmus Medical Center

Rotterdam
Netherlands

-

Study participating centre

Institute Verbeeten

Tilburg
Netherlands

-

Study participating centre

Isala Clinics

Zwolle
Netherlands

-

Study participating centre

Maastricht Radiation Oncology Clinic

Maastricht
Netherlands

-

Study participating centre

Medical Centre Haaglanden

Den Haag
Netherlands

-

Study participating centre

NKI/Antoni v. Leeuwenhoekhuis (The Netherlands Cancer Institute)

Amsterdam
Netherlands

-

Study participating centre

Radiotherapy Group, Arnhem

Arnhem

Netherlands

-

Study participating centre

Radiotherapy Institute Friesland, Leeuwarden

Leeuwarden

Netherlands

-

Study participating centre

University Medical Center Groningen

Groningen

Netherlands

-

Study participating centre

University Medical Center Radboud

Nijmegen

Netherlands

-

Study participating centre

University Medical Center Utrecht

Utrecht

Netherlands

-

Study participating centre

Zuidwest Radiotherapy Institute

Vlissingen

Netherlands

-

Study participating centre

University Hospital Gent

Corneel Heymanslaan 10

Gent

Belgium
9000

Study participating centre
University Hospital Tübingen
Hoppe-Seyler-Straße 3
Tübingen
Germany
72076

Study participating centre
Rotkreuzklinikum München
Rotkreuzpl. 8
München
Germany
80634

Study participating centre
Kliniken Essen-Mitte
Henricistraße 92
Essen
Germany
45136

Study participating centre
Universitätsklinikum Schleswig-Holstein
Campus Lübeck
Ratzeburger Allee 160
Lübeck
Germany
23562

Study participating centre
Kaiserswerther Diakonie Düsseldorf
Kreuzbergstraße 79
Düsseldorf
Germany
40489

Study participating centre
Universitätsklinikum Heidelberg
Im Neuenheimer Feld 672
Heidelberg
Germany
69120

Study participating centre
Sankt Gertrauden Krankenhaus Berlin
Paretzer Straße 12
Berlin
Germany
10713

Study participating centre
Kantonsspital Frauenklinik Lucerne
Spitalstrasse
PO Box 6000
Luzern
Switzerland
16

Study participating centre
Saint Luke's Radiation Oncology Network (SLRON), Dublin
Oakland Drive
Highfield Road
Dublin
Ireland
6

Study participating centre
St James's Hospital (SJH), Dublin
James Street
Dublin
Ireland
8

Study participating centre
University Hospital Prague
U Nemocnice 499/2
Prague

Czech Republic
128 08

Study participating centre
Institut Gustave-Roussy, Paris
114, rue Édouard-Vaillant
Villejuif Cedex
France
94805

Study participating centre
Hôpital Européen Georges-Pompidou, Paris
20 Rue Leblanc
Paris
France
75015

Study participating centre
Hôpital Tenon, Paris
4 Rue de la Chine
Paris
France
75020

Study participating centre
Medical University, Vienna
Spitalgasse 23
Wien
Austria
1090

Sponsor information

Organisation
Leiden University Medical Center

ROR
<https://ror.org/05xvt9f17>

Funder(s)

Funder type

Charity

Funder Name

KWF Kankerbestrijding

Results and Publications

Individual participant data (IPD) sharing plan

After publication of the full results (including long-term results) the de-identified data will be available for relevant scientific studies, upon request and submission of a research proposal, and after evaluation of the PORTEC-group.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2018		Yes	No
Results article	Brachytherapy quality assurance	05/11/2020	17/08/2021	Yes	No
Results article		01/01/2026	06/01/2026	Yes	No
Protocol article		12/10/2020	17/08/2021	Yes	No
Participant information sheet	Short patient information in English		17/08/2021	No	Yes
Participant information sheet	v2.2	09/04/2016	17/08/2021	No	Yes
Participant information sheet	v2.5.1	26/06/2020	17/08/2021	No	Yes
Participant information sheet		11/11/2025	11/11/2025	No	Yes
Study website		11/11/2025	11/11/2025	No	Yes